Research
    Li Wei
    Title Deputy Director, Associate chief physician and advisor of master’s degree students
    Profile

    Dr. Li Wei graduated from former Sun Yat-sen University of Medical Sciences in 1990 and since then has worked in the Department of Anesthesia at Sun Yat-sen University Cancer Center. He specializes in the anesthesia for various tumor operations and treatment of critically ill patients.

    Email
    Phone
    Research Interest(s) One-lung ventilation; treatment of serious and life-threatening diseases 
    Education
    Publications Li Wei,Anerthesiology,Sun Yat-sen University Cancer Center
    Zeng Weian
    Title Lead Physician, doctoral advisor, Department of Anesthesiology
    Profile

    Dr. Wei-an Zeng is a professor of clinical anesthesia and Leading for Department of Anesthesiology & Operating Theatre of Sun Yat-sen University Cancer Center (SYSUCC). He obtained his Medical Degree at Nagoya University and Ph.D. at Gifu University, Japan from 1989 to 1998. Then he continues his research as a research scholar in Gifu University until 1999. He joined the Department of Anesthesia at SYSUCC in April 1999. In 2011, Dr. Zeng appointed as the Director of Anesthesia Department.

    Dr Zeng’s research is focused on Anesthesia, Analgesia and Neuropathic pain. He have 5 research programme are funded by the National Science Foundation and have published more than 40 articles in scientific journals, such as Anesthesiology, J Pain, BJA, Ann Surg Oncol, Anesth Analg and CJA, etc.

    Email zengwa@sysucc.org.cn
    Phone
    Research Interest(s)

    Anesthesia, Analgesia and Neuropathic pain.

    Education

    12/1989-05/1992: Master’s degree student at Nagoya University Graduate School of Medicine, Japan.

    11/1993-10/1998: Ph.D. student at Gifu University, Japan.

    11/1998-03/1999: Research scholar at Gifu University Graduate School of Medicine, Japan.

    Publications

    1) JTC-801 alleviates mechanical allodynia in paclitaxel-induced neuropathic pain through the PI3K/Akt pathway. European Journal of Pharmacology. 2020 S0014-2999(20)30398-8. doi.org/10.1016/j.ejphar.2020.173306. (*)

    2) Nuclear Factor-kappaB Gates Nav1.7 Channels in DRG Neurons via Protein-Protein Interaction. iScience. 2019 Aug 10;19:623-633. doi: 10.1016/j.isci.2019.08.017. [Epub ahead of print].

    3) Antinociceptive effectiveness of the inhibition of NCX reverse-mode action in rodent neuropathic pain model. Mol Pain. 2019 Jan-Dec;15:1744806919864511. doi: 10.1177/1744806919864511. (*)

    4) Sevoflurane promotes migration, invasion, and colony-forming ability of human glioblastoma cells possibly via increasing the expression of cell surface protein 44. Acta Pharmacol Sin. 2019 Apr 9. doi: 10.1038/s41401-019-0221-0. [Epub ahead of print].

    5) Puerarin Relieves Paclitaxel-Induced Neuropathic Pain: The Role of Nav1.8 β1 Subunit of Sensory Neurons. Front Pharmacol. 2019 Jan 7;9:1510. doi: 10.3389/fphar.2018.01510. eCollection 2018.

    6) Dexmedetomidine Protects Against Chemical Hypoxia-Induced Neurotoxicity in Differentiated PC12 Cells Via Inhibition of NADPH Oxidase 2-Mediated Oxidative Stress. Neurotox Res. Neurotox Res. 2019 Jan;35(1):139-149. doi: 10.1007/s12640-018-9938-7. Epub 2018 Aug 15. (*)

    7) The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target. Br J Anaesth. 2019 Jun;122(6):e157-e167. doi: 10.1016/j.bja.2018.09.030. Epub 2018 Dec 12. (*)

    8) Bulleyaconitine A attenuates hyperexcitability of dorsal root ganglion neurons induced by spared nerve injury: The role of preferably blocking Nav1.7 and Nav1.3 channels. Mol Pain. 2018 Jan-Dec;14:1744806918778491. doi: 10.1177/1744806918778491.

    9) Amantadine attenuates sepsis-induced cognitive dysfunction possibly not through inhibiting toll-like receptor 2. J Mol Med (Berl). 2018 May;96(5):391-402.

    10) Calpain-2 Regulates TNF-α Expression Associated with Neuropathic Pain Following Motor Nerve Injury. Neuroscience. 2018 Feb 23;376:142-151.

    11) Early CALP2 expression and microglial activation are potential inducers of spinal IL-6 upregulation and bilateral pain following motor nerve injury. J Neurochem. 2018 Feb 9. doi: 10.1111/jnc.14317. [Epub ahead of print].

    12) AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4. Brain Behav Immun. 2018 Feb;68:158-168.

    13) Synergistic Interaction Between Dexmedetomidine and Ulinastatin Against Vincristine-Induced Neuropathic Pain in Rats. J Pain. 2017 Nov;18(11):1354-1364.

    14) Down-regulation ofthe tumour suppressor κ-opioid receptor predicts  poor prognosis in hepatocellular carcinoma patients. BMC Cancer. 2017 Aug 18;17(1):553. (*)

    15) The Prognostic Value of Peripheral Benzodiazepine Receptor in Patients with Esophageal Squamous Cell Carcinoma. Journal of Cancer 2017, Vol. 8 2017; 8(16): 3343-3355. (*)

    16) Lidocaine Induces Apoptosis and Suppresses Tumor Growth in Human Hepatocellular Carcinoma Cells In Vitro and in a Xenograft Model In Vivo. Anesthesiology. 2017 May;126(5):868-881. (*)

    17) Internal jugular vein versus subclavian vein as the percutaneous insertion site for totally implantable venous access devices: a meta-analysis of comparative studies. BMC Cancer. 2016 Sep 22;16(1):747. (*)

    18) Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy. Cancer Biomark. 2016 Jun 7;17(1):89-96. (*)

    19) Ulinastatin attenuates neuropathic pain induced by L5-VRT via the calcineurin/IL-10 pathway. Molecular Pain. Volume 12: 1–9. (*)

    20) Presynaptic N-Methyl-d-aspartate (NMDA) Receptor Activity Is Increased Through Protein Kinase C in Paclitaxel-induced Neuropathic Pain. J Biol Chem. 2016 Sep 9;291(37):19364-73.

    21) Fentanyl enhances hepatotoxicity of paclitaxel via inhibition of CYP3A4 and ABCB1 transport activity in mice. PLoS One. 2015 Dec 3;10(12):e0143701. (*)

    22) Spinal antinociceptive action of amiloride and its interaction with tizanidine in the rat formalin test. Pain Res Manag. 2015 Nov-Dec;20(6):321-6. (*)

    23) Antinociceptive effect of intrathecal amiloride on neuropathic pain in rats. Neurosci Lett. 2015 Jul 28;604:24-29. (*)

    24) Sevoflurane protects against intestinal ischemia-reperfusion injury partly by phosphatidylinositol 3 kinases/Akt pathway in rats. Surgery. 2015 May;157(5):924-33.

    25) Impact of preoperative anemia on relapse and survival in breast cancer patients. BMC Cancer. 2014 Nov 18;14:844. (*)

    26) Anti-inflammatory and antinociceptive activities of bufalin in rodents. Mediators Inflamm. 2014;2014:171839. (*)

    27) Long-term survival after resection of hepatocelluar carcinoma: a potential risk associated with the choice of postoperative analgesia. Anesth Analg. 2014 Jun;118(6):1309-16. (*)

    28) HSV-mediated p55TNFSR reduces neuropathic pain induced by HIV gp120 in rats through CXCR4 activity. Gene Ther. 2014 Mar;21(3):328-36.

    29) Mechanical allodynia induced by nucleoside reverse transcriptase inhibitor is suppressed by p55TNFSR mediated by herpes simplex virus vector through the SDF1α/CXCR4 system in rats. Anesth Analg. 2014 Mar;118(3):671-80.

    30) Real-time Two-dimensional Ultrasound Guidance for Central Venous Cannulation: A Meta-analysis. Anesthesiology. 2013 Feb;118(2):361-75. (*)

    31) The antinociceptive activity of intrathecally administered amiloride and its interactions with morphine and clonidine in rats. J Pain. 2012 Jan;13(1):41-8. (*)

    32) The Beta2-Adrenergic Receptor is a Potential Prognostic Biomarker for Human Hepatocellular Carcinoma After Curative Resection. Ann Surg Oncol. 2012 Oct;19(11):3556-65. (*)

    33) The effects of anesthetic technique on cancer recurrence in percutaneous radiofrequency ablation of small hepatocellular carcinoma. Anesth Analg. 2012  Feb;114(2):290-6.

    34) The antinociceptive effect of intrathecal escin in the rat formalin test. Eur J Pharmacol. 2012 Jan 15;674(2-3):234-8. (*)

    35) Risk factors for anastomotic leakage following anterior resection for colorectal cancer: the effect of epiduralanalgesia on occurrence. Int J Colorectal Dis. 2013 Apr;28(4):485-92. (*)

    36) An emerging new paradigm in opioid withdrawal: a critical role for glia-neuron signaling in the periaqueductal gray. Scientific World Journal. 2012:940613. 

    37) Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis. Br J Anaesth. 2011 Jun;106(6):814-22. (*)

    38) Mechanisms of antinociceptive effects of ouabain in combination with neostigmine in the rat. Neural regeneration research 2008.3(7): 710-3. (*)

    39) Antinociceptive Synergistic Interaction between Clonidine and Ouabain on Thermal Nociceptive Tests in the Rat. J Pain 2007.8(12): 983-8. (#)

    40) Effects of succinylcholine on spinal antinociception with lidocaine in rats. Acute Pain 2005; 7(1):37-42. (*)

    41) Spinal antinociceptive action of Na+–K+ pump inhibitor ouabain and it interaction with morphine and lidocaine in rats. Anesthesiology 1999; 90: 500-8. (#)




    Updated July 2020 by International Office, Sun Yat-sen University Cancer Center

    Xu Meixi
    Title Associate chief physician and Deputy Director
    Profile

    Dr. Xu Meixi graduated from Oncology at former Zhongshan Medicine School in October, 1983. He has been engaged in anesthesia for 26 years, taking charge of the anesthesia and management of different specialized surgeries, including thoracic surgery, hepatobiliary surgery, head and neck surgery, craniocerebral surgery, abdominal surgery, gynecological cancer, urology and pediatric surgery. He is adept at anesthetic techniques for one-lung ventilation and diverse methods of difficult airway treatment, such as awake nasotracheal intubation, fibreoptic nasotracheal intubation and esophageal & endotracheal intubation. He is proficient in anesthesia for patients with tracheobronchial tumor & severe tracheal stenosis as well as perioperative invasive monitoring technology.

    Work Experience
    10/1983-07/1993: Resident physician, Department of Anesthesia at Sun Yat-sen University Cancer Center;

    08/1993-10/2001: Attending physician, Department of Anesthesia at Sun Yat-sen University Cancer Center;

    06/2002: Obtained the qualification of associate chief physician; employed as the associate chief physician by Sun Yat-sen University;

    Present: Member of the Standing Committee of Guangdong Medical Association Society of Anesthesiology and Member of the Standing Committee of Guangdong Medical Doctor Association Society of Anesthesiologists

    Email
    Phone
    Research Interest(s)

    One-lung ventilation; treatment of serious and life-threatening diseases

    Education
    Publications

    Updated by International Office, Sun Yat-sen University Cancer Center

    Cao Longhui
    Title Associate chief physician, advisor of master’s degree students
    Profile

    Dr. Cao Longhui has been working in Department of Anesthesia at Sun Yat-sen University Cancer Center since her graduation from Zhongshan School of Medicine, SYSU in 2001. She was conferred upon the Master’s Degree in Clinical Medicine by Sun Yat-sen University in 2005 and upon the Doctoral Degree in Clinical Medicine by Sun Yat-sen University in 2010. She was then employed as the associate chief physician in 2012. From February 2010 to January 2011, she pursued her advanced studies in Thomas Jefferson University in the United States. She has carried out and participated in a multitude of research and clinical work. She mainly researches the mechanism of anesthetic drugs, the relationship between anesthetic drugs and the occurrence, development and metastasis of malignant tumors as well as one-lung ventilation lung injury. Currently she is undertaking one program of NSFC Youth Science Foundation.

    Email
    Phone
    Research Interest(s)
    Education
    Publications

    1. Cao L, Young N, Liu H, Silvestry S, Sun W, Zhao N, Diehl J, Sun J. Preoperative Aspirin Use and Outcomes in Cardiac Surgery Patients. Ann Surg 2012;255(2):399-404. (IF:6.329)


    2. Cao L, Silvestry S, Zhao N, Diehl J, Sun J.  Effects of preoperative aspirin on cardiocerebral and renal complications in non-emergent cardiac surgery patients: a sub-group and cohort study. PLoS One 2012;7(2):e30094. (IF:3.730)


    3. Cao L, Chang Y, Lin W, Zhou J, Tan H, Yuan Y, Zeng W. Long-term Survival after resection of hepatocellular carcinoma: A potential risk associated with the choice of postoperative analgesia. Anesth Analg. 2014 Jun; 118(6):1309-16. (IF:3. 30)

    4. Zhou JH, Cao LH, et al.Contrast-enhanced gray-scale ultrasound for quantitative evaluation of tumor response to chemotherapy: preliminary results with a mouse hepatoma model. AJR Am J Roentgenol 2011;196 (1):W13-W17. (IF:2.897)(co-first authors)


    5. Lin CY, Cao LH, et al. Ultrasonic spectrum analysis for in vivo characterization of tumor microstructural changes in the evaluation of tumor response to chemotherapy using diagnostic ultrasound.. BMC Cancer 2013;13:302. (IF:3.33). (co-first authors)


    6. Sun JZ, Cao LH, et al.ACE inhibitors in cardiac surgery: current studies and controversies. Hypertens Res 2011; 34(1):15-22. (IF: 2.426)


    7. Zhou JH, Cao LH, et al. Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US. Radiology; 2011;259(2):406-13 (IF: 6.339)


    8. Zhou JH, Zheng W, Cao LH, et al. Quantitative evaluation of viable tissue perfusion changes with contrast-enhanced greyscale ultrasound in a mouse hepatoma model following treatment with different doses of thalidomide. Br J Radiol 2011;84(1005):826-32 (IF: 1.217)


    9. Zhou JH, Zheng W, Cao LH, et al. Contrast-enhanced ultrasonic parametric perfusion imaging in the evaluation of antiangiogenic tumor treatment. Eur J Radiol 2011 Feb 21. (IF:2.941)


    10. Zhou JH, Zheng W, Cao LH, et al. Antiangiogenic tumor treatment noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound. Acad Radiol 2010; 17(5):646-651. (IF: 2.195)


    11. Zhou JH, Li AH, Cao LH, et al. Haemodynamic parameters of the hepatic artery and vein can detect liver metastases: the assessment using contrast-enhanced ultrasound. Br J Radiol 2008; 81(2):113-119. (IF: 2.062)


    12. Wu SY, Ling Q, Cao LH, et al.Real-time two-dimensional ultrasound guidance for central venous cannulation.:a meta-analysis. Anesthesiology;2013,118(2) (IF:5.163)


    13. Wang JW, Zheng W, Chen Y, Cao LH, Luo RZ, Li AH, Zhou JH. Quantitative assessment of tumor blood flow changes in a murine breast cancer model after adriamycin chemotherapy using contrast-enhanced destruction-replenishment sonography. J Ultrasound Med. 2013; 32(4):683-90. (IF:1.402)


    14. Wang JW, Zheng W, Liu JB, Chen Y, Cao LH, Luo RZ, Li AH, Zhou JH. Assessment of early tumor response to cytotoxic chemotherapy with dynamic contrast-enhanced ultrasound in human breast cancer xenografts. PLoS One 2013; 8(3):e58274.( IF:3.73)




    Updated by International Office, Sun Yat-sen University Cancer Center



    He Weixiong
    Title Associate chief physician
    Profile

    Dr. He Weixiong graduated from the Anesthesia Class, Department of Medicine at former Sun Yat-sen University of Medical Sciences in 1991. He specializes in anesthesia for various tumor operations and treatment of critically ill patients.

    Email
    Phone
    Research Interest(s)

    One-lung ventilation, pain treatment

     

    Education
    Publications

    1. Mechanisms of antnociptive effects of ouabain in combination with neostigmine in the rat. Neural Regeneration Research,2008,3:710-713

     


    Updated by International Office, Sun Yat-sen University Cancer Center



Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.